Risdiplam (Evrysdi)
Small molecule
Also known as RO7034067
Evidence outlook
Approved: Spinal Muscular Atrophy
Regulatory approval supersedes design-level evidence grading; the trials behind approval are preserved below as the drug's evidence history.
Also approved (2)
- Treatment of spinal muscular atrophy
- Evrysdi is indicated for the treatment of 5q spinal muscular atrophy (SMA) in patients with a clinical diagnosis of SMA Type 1, Type 2 or Type 3 or with one to four SMN2 copies.
How the evidence outlook works ↗
Featured trials
The studies most instrumental to this drug's clinical progression, individually graded on design and result. The complete registry, including every study not featured here, is listed below.
| Trial | Phase | Endpoint | Key result | Signal | Source |
|---|---|---|---|---|---|
FIREFISH NCT02913482 · Spinal Muscular Atrophy Registry: NCT02913482 | 2 | Part 1: Selected Part 2 Dose of Risdiplam (Minimum of 2 weeks at steady state exposure); Part 2: Percentage of Infants Who Are Sitting Without Support for at Least 5 Seconds as Assessed by Item 22 of the Gross Motor Scale of the Bayley Scales of Infant and Toddler Development Third Edition (BSID-III) at Month 12 2019-11-14 | Completed. Key figures are not recorded here. | not yet graded | link ↗ |
View 2 more trials
SUNFISH NCT02908685 · Spinal Muscular Atrophy Registry: NCT02908685 | 2 | Part 1: Selected Part 2 Dose of Risdiplam for Participants With a Body Weight (BW) of >/=20kg (Day 1 up to at least 4 weeks on study (Up to CCOD of 25 July 2017)); Part 1: Selected Part 2 Dose of Risdiplam for Participants With BW of <20kg (Day 1 up to at least 4 weeks on study (Up to CCOD of 25 July 2017)); Part 2: Change From Baseline in the Total Motor Function Measure 32 (MFM-32) Total Score at Month 12 (Baseline (Day-1) and Month 12) 2019-09-06 | Completed. Key figures are not recorded here. | not yet graded | link ↗ |
Rainbowfish NCT03779334 · Spinal Muscular Atrophy Registry: NCT03779334 | 2 | Percentage of Participants With Two Copies of the Survival Motor Neuron (SMN) 2 Gene (Excluding the Known SMN2 Gene Modifier Mutation c.859G>C) and Baseline Compound Muscle Action Potential (CMAP) >=1.5 Millivolt (mV) Who Are Sitting Without Support (At Month 12) 2023-02-20 | Results posted on ClinicalTrials.gov. Key figures are not recorded here. | not yet graded | link ↗ |
All registered studies
Every ClinicalTrials.gov study of this drug's own program. Studies backing a featured trial above are marked Featured; the rest aren't individually graded. Filter by which indication a study was run for, then browse by phase. Studies where this drug served as another program's comparator, or is merely referenced, are listed separately below.
Phase 3 (2)
What this study did
What this study did
Phase 2 (6)
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
Phase 1 (6)
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
Phase 4 (4)
What this study did
What this study did
What this study did
What this study did
Appears in other studies (1)
Studies that reference this drug without giving it an intervention arm of its own: other formulations' programs, background therapy, or registry-search bleed.
Phase 2/3 (1)
What this study did
Competitive landscape
Other SMN2 pre-mRNA drugs
1 other tracked programme targets this mechanism, none of them ahead of this one.
This drug's own stage for Spinal Muscular Atrophy: Approved. Competitors below are sorted furthest-along first.
| Drug | Stage | Modality | Mechanism | Evidence signal | Reported efficacygraded featured trials | |
|---|---|---|---|---|---|---|
| Risdiplam (Evrysdi): this drug | Approved | Small molecule | SMN2 pre-mRNA | not yet graded | No reviewed efficacy summary in this indication | |
| Apitegromab (Isembyld) | Approved | Monoclonal antibody | Myostatin (pro/latent form) | not yet graded | No reviewed efficacy summary in this indication | |
| Nusinersen (Spinraza) | Approved | RNA / oligonucleotide | SMN2 pre-mRNA | Weak signal | NCT02292537: Change From Baseline in Hammersmith Functional Motor Scale - Expanded (HFMSE) Score at Month 15 (Baseline and Month 15): Sham Procedure -1 scores on a scale (95% CI -2.5 to 0.5) | Nusinersen 3.9 scores on a scale (95% CI 3 to 4.9) NCT01839656: Percent of Participants Who Achieved Improvement in Motor Milestones as Assessed by Section 2 of the HINE at the Last Visit (Day 1352 or Early Termination): Nusinersen 6 mg 25 Percent of participants | Nusinersen 12 mg 68.8 Percent of participants | |
| Taldefgrobep Alfa | Phase 3 | Antibody-derived scaffold | Activin/myostatin type II receptor | not yet graded | No reviewed efficacy summary in this indication |
Compare side by side
Upcoming events
(4 total)
Estimated primary-completion dates from ClinicalTrials.gov. These are registry estimates, never confirmed readout dates; they can move as trials progress.
Follow Risdiplam (Evrysdi) to get an email as a readout nears, when a date moves, or when a study changes status. Needs a free account.
Add these readouts to your calendar: Apple or Outlook · Google Calendar · .ics link. The calendar updates when a registry date moves.